Hint mode is switched on Switch off
For swift navigation between sections

Amgen, 4.4% 22feb2062, USD (FIGI BBG015GXJYK0, WKN A3K2PU)

Download
Copy issue information to clipboard
Copy issue information to clipboard
Copy to clipboard
Data copied to the clipboard

PDF download

Choose all Reset all
Download Cancel

FIND, SAVE & TRACK INVESTMENTS WITH CBONDS WATCHLIST

With Cbonds Watchlist you can always stay updated on your investments to make conscious decisions!

Watchlist
You need to request access

International bonds, Trace-eligible, Senior Unsecured

Issue | Borrower
Borrower
  • M
    ***   | ***
    ***
  • S&P
    ***   | ***
    ***
  • F
    ***   | ***
    ***
Status
Outstanding
Amount
1,250,000,000 USD
Placement
***
Redemption (put/call option)
*** (-)
ACI
Country of risk
USA
Current coupon
***%
Price
Yield / Duration
  • Placement amount
    1,250,000,000 USD
  • Outstanding amount
    1,250,000,000 USD
  • USD equivalent
    1,250,000,000 USD
  • Minimum Settlement Amount
    2,000 USD
  • CFI
    DBFNGR
  • FIGI
    BBG015GXJYK0
  • SEDOL
    BPY0TJ2
  • Ticker
    AMGN 4.4 02/22/62
Cbonds API

Get Financial Data Automatically via API

Receive pricing and descriptive data for

  • Bonds
  • Stocks
  • Indices
  • ETFs
  • Funds
  • Global data coverage: Descriptive data, Prices, cash flow, bond prospectuses, IFRS reports
  • Easy Integration: API • Data Feeds • Web Services
  • Transparent Pricing: Tailored to your needs
Free Plan

Start exploring global markets in less than 1 minute

  • 100,000+ Stocks
  • 17,000+ ETFs
  • 150,000+ Mutual Funds
  • Global Macro & Commodity Data
  • Research Hub & Basic Market News
  • AI Bond Screener
Free Plan
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Unlock data Watch full tour

Files

Final Terms

Prospectus

Trading chart

Stock exchange selection
Stock exchange selection
More about Cbonds Estimation
No more than two exchanges can be selected for comparison at the same time
Data display in a chart | table
Data display in a chart | table
Work with the chart: switching the price, period, issue comparison
Work with the chart: switching the price, period, issue comparison
Customize fields in the table
Found:
Show all fields
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
* Data is not available within the selected subscription

Explore the most comprehensive database

1 000 000

bonds

100 000

stocks

175 910

ETF & Funds

100 000

indices

Track your portfolio in the most efficient way

  • Bond Search
  • Watchlist
  • Excel ADD-IN
Get access
×

— Are you looking for the complete & verified bond data?

— We have everything you need:

full data on over 1 000 000 bonds, 100 000 stocks, 100 000 indices, 17 000 ETF and 150 000 Mutual Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.

Register
×

Why

You will have detailed descriptive & pricing data for 1M bonds, 100K stocks, 100K indices, 17K ETF and 150K Mutual Funds
Get full access to the platform from any device & via Cbonds app
Enhance your portfolio management with Cbonds Excel Add-in
Build yield maps, make chart comparison within a click
Don't wait any longer — start using Cbonds today! Register

Issue information

Profile
Amgen Inc. is an American multinational biopharmaceutical company headquartered in California. Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel ...
Amgen Inc. is an American multinational biopharmaceutical company headquartered in California. Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.
Show more Hide
Research report by Cbonds-PRAAMS Save
Authorization required
Report download is available only paid Premium subscription access
Volume
  • Placement amount
    1,250,000,000 USD
  • Outstanding amount
    1,250,000,000 USD
  • Outstanding face value amount
    1,250,000,000 USD
Face value
  • Minimum Settlement Amount
    2,000 USD
  • Outstanding face value
    *** USD
  • Increment
    *** USD
  • Face value
    1,000 USD

Get access to the largest bond database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest bond database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Cash flow parameters

  • Reference rate
    ***
  • Coupon Rate
    ***
  • Day count convention
    ***
  • Interest Accrual Date
    ***
  • Coupon frequency
    *** time(s) per year
  • Payment currency
    ***
  • Maturity date
    ***

Cash flow

Calculations for international bonds are made according to the minimum trading lot
Export to Excel

Early redemption terms

***

Explore the most comprehensive database

1 000 000

bonds

100 000

stocks

175 910

ETF & Funds

100 000

indices

Track your portfolio in the most efficient way

  • Bond Search
  • Watchlist
  • Excel ADD-IN
Get access
×

— Are you looking for the complete & verified bond data?

— We have everything you need:

full data on over 1 000 000 bonds, 100 000 stocks, 100 000 indices, 17 000 ETF and 150 000 Mutual Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.

Register
×

Why

You will have detailed descriptive & pricing data for 1M bonds, 100K stocks, 100K indices, 17K ETF and 150K Mutual Funds
Get full access to the platform from any device & via Cbonds app
Enhance your portfolio management with Cbonds Excel Add-in
Build yield maps, make chart comparison within a click
Don't wait any longer — start using Cbonds today! Register

Placement

  • Placement method
    Open subscription
  • Placement type
    Public
  • Placement
    ***
  • Initial issue price (yield)
    (***%)
  • Geographic breakdown
    ***
  • Investor breakdown
    ***
  • Use of proceeds
    General Corporate Purposes
    Refinance
    Working Capital
    Stock Buyback
    Investment
  • Use of proceeds description
    The company estimates that the net proceeds from the sale of the the 2032 notes, the 2052 notes and the 2062 notes will be approximately $3,205,534,944 after deducting the underwriting discounts and estimated pro rata expenses related to the offering of the the 2032 notes, the 2052 notes and the 2062 notes. The company intends to use the net proceeds from the sale of the 2032 notes, the 2052 notes and the 2062 notes in this offering for general corporate purposes, including, but not limited to, repurchasing shares of our common stock pursuant to our stock repurchase program, working capital, investments in our business, and upcoming debt maturities.
Participants
  • Bookrunner
    ***, ***, ***, ***, ***, ***, ***, ***
  • Depository
    ***, ***, ***

Conversion and exchange

  • Conversion terms
    ***

Covenants

Authorization required
You need to request access

Issue is included in calculation of indices

Cbonds USA Corporate BBB Duration Index
Cbonds USA Corporate BBB G-Spread Index
Cbonds USA Corporate BBB Index TR
Cbonds USA Corporate BBB Price Index
Cbonds USA Corporate BBB T-Spread Index
Cbonds USA Corporate BBB YTM Index
Show more Hide

Latest issues

Show all

Similar issues

News

21/08/2026 Here's Why Amgen (AMGN) is a Strong Momentum Stock
04/08/2026 BMY or AMGN: Which Is the Better Value Stock Right Now?
01/08/2026 Affiliated Managers Group (NYSE: AMG) Demonstrates Strong Financial Performance and Growth in Asset Management
29/07/2026 Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients
29/07/2026 Amgen: Material Cybersecurity Incidents
All organization news

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
II q eng
III q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show more Hide
Authorization required
You need to request access

Identifiers

  • ISIN
    ***
  • Cbonds ID
    1218903
  • CUSIP
    ***
  • CUSIP 144A
    ***
  • CFI
    DBFNGR
  • FIGI
    BBG015GXJYK0
  • WKN
    A3K2PU
  • SEDOL
    BPY0TJ2
  • Ticker
    AMGN 4.4 02/22/62
  • Type of security by CBR
    ***

Ratings

Bond classification

  • Senior Unsecured
  • Registered
  • Coupon bonds
  • Trace-eligible
  • Amortization
  • Callable
  • CDO
  • Convertible
  • Dual currency bonds
  • Variable rate
  • For qualified investors (CIS region)
  • Foreign bonds
  • Green bonds
  • Guaranteed
  • Inflation-linked principal
  • Supranational bond issues
  • Inflation-linked coupon
  • Mortgage bonds
  • Non-complex financial instruments (MiFID)
  • Perpetual
  • Payment-in-kind
  • Non-Marketable Securities
  • Redemption Linked
  • Restructuring
  • Retail bonds
  • Covered
  • Securitization
  • Structured product
  • Commercial Bonds
  • Subordinated
  • Sukuk
Show more Hide

Restructuring

***

Holders

Registration is required to get access.